Everolimus With Reduced Cyclosporine Versus MMF With Standard Cyclosporine in De Novo Heart Transplant Recipients-Reference-Cited by-同舟云学术

Everolimus With Reduced Cyclosporine Versus MMF With Standard Cyclosporine in De Novo Heart Transplant Recipients

Published:2009-07-15 Issue:1 Volume:88 Page:115-122
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Lehmkuhl Hans B.,Arizon José,Viganò Mario,Almenar Luis,Gerosa Gino,Maccherini Massimo,Varnous Shaida,Musumeci Francesco,Hexham J Mark,Mange Kevin C.,Livi Ugolino

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference11 articles.

1. Calcineurin inhibitors in heart transplantation.;Keogh;J Heart Lung Transplant,2004

2. Calcineurin inhibitors in heart transplantation.;Crespo-Leiro;Transplant Proc,2005

3. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.;Eisen;N Engl J Med,2003

4. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.;Vitko;Am J Transplant,2004

5. 36 months analysis on efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral® in de novo kidney transplant recipients.;Tedesco;Transplantation,2006

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mTor‐inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy;Pediatric Transplantation;2024-03

2. Wound complications frequency in heart transplant recipients on mammalian target of rapamycin inhibitors: A meta‐analysis;International Wound Journal;2023-05-10

3. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients;The Journal of Heart and Lung Transplantation;2023-05

4. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients;The Journal of Heart and Lung Transplantation;2022-12

5. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients;Atherosclerosis;2022-09